Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5709596 | 0.91 | REN (0.47) | REN | |
| SCHEMBL5709673 | 0.91 | REN (0.54) | REN | |
| SCHEMBL5709571 | 0.82 | REN (0.62) | REN | |
| SCHEMBL5709648 | 0.82 | REN (0.62) | REN | |
| SCHEMBL5709572 | 0.80 | REN (0.49) | REN | |
| SCHEMBL5709629 | 0.74 | REN (0.60) | REN | |
| SCHEMBL7411200 | 0.74 | REN (0.66) | REN | |
| SCHEMBL7408319 | 0.73 | REN (0.65) | REN | |
| SCHEMBL9800473 | 0.67 | REN (0.62) | REN | |
| SCHEMBL5709573 | 0.67 | REN (0.54) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | SCHOSTAREZ HEINRICH J (US) | 2005-04-14 | — | — | US | claimed |
| US-5246969-A | Oligopeptides as renin inhibitors | G. D. SEARLE & CO. (US) | 1993-09-21 | — | — | US | claimed |
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | SCHOSTAREZ HEINRICH J (US) | 2005-04-14 | — | — | US | disclosed |
| US-5461074-A | Dipropargyl containing aryl/alkyl sulfur/or sulfonyl/or sulfoxide terminated aminodiol compounds are used as renin inhibitor; therpeutical | G.D. SEARLE & CO. (US) | 1995-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | BACE1, BACE2, APP | REN 2199/4885MMP2 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.